To access this element change to forms mode OFF
Grant Award View - GA214907
A First-In-Class Tumour Matrix Targeting Approach to Enhance...
GA ID:
GA214907
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
21-Nov-2021
Publish Date:
24-Jan-2022
Category:
Health and Medical Research
Grant Term:
1-Jan-2022 to 31-Jan-2025
Value (AUD):
$836,602.72
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
A First-In-Class Tumour Matrix Targeting Approach to Enhance Chemotherapy in Pancreatic Cancer
Purpose:
Chemotherapy is the standard-of-care for pancreatic cancer patients. Whilst chemotherapy initially works, it quickly becomes ineffective and patients go on to relapse. One reason for this failure is chemotherapy-induced scarring (fibrosis) in and around the tumour. This scarring blunts the effectiveness of subsequent rounds of treatment. Our preliminary data show that our novel compound can block this scar formation offering a novel stromal targeting approach to improve chemotherapy efficacy.
GO ID:
GO Title:
NHMRC Development Grants 2021 for funding in 2022
Internal Reference ID:
2021/GNT2013881
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA